A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host Disease
Latest Information Update: 26 Dec 2022
At a glance
- Drugs OSSM-001 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Ossium Health
Most Recent Events
- 21 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Jul 2022 New trial record